deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs
News Feb 09, 2009
deCODE chemistry & biostructures has announced the initiation of a collaboration with UCB. Under the terms of the deal, deCODE and UCB will collaborate on the structure-based discovery of small molecule modulators of undisclosed cytokine targets.
The program will focus on integrated structure-based drug design leveraging deCODE’s Fragments of Life™ technology for lead identification and optimization. As the program advances, it may also capitalize on deCODE's expertise in ADMET and PK/PD. The financial terms of the research fee, milestone and royalty-bearing relationship were not disclosed.
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE